Obstructive sleep apnea treatment, slow wave activity, and amyloid‐β

• Published in: Annals of neurology Vol. 85; no. 2; pp. 291 - 295
• Main Authors: Ju, Yo‐El S., Zangrilli, Margaret A., Finn, Mary Beth, Fagan, Anne M., Holtzman, David M.
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.02.2019; Wiley Subscription Services, Inc
• Subjects: Aged; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Apnea; Cerebrospinal fluid; Continuous Positive Airway Pressure; Dementia disorders; Female; Humans; Male; Middle Aged; Neurodegenerative diseases; Peptide Fragments - cerebrospinal fluid; Sleep; Sleep apnea; Sleep Apnea, Obstructive - cerebrospinal fluid; Sleep Apnea, Obstructive - therapy; Sleep Deprivation - cerebrospinal fluid; Sleep disorders; Sleep, Slow-Wave; tau Proteins - cerebrospinal fluid; Treatment Outcome
• ISSN: 0364-5134; 1531-8249
• DOI: 10.1002/ana.25408

Obstructive sleep apnea (OSA) increases risk of dementia, a relationship that may be mediated by amyloid‐β (Aβ) and downstream Alzheimer disease pathology. We previously showed that OSA may impair Aβ clearance and affect the relationship between slow wave activity (SWA) and Aβ. In this study, SWA and CSF Aβ were measured in participants with OSA before and 1 to 4 months after treatment. OSA treatment increased SWA, and SWA was significantly correlated with lower Aβ after treatment. Greater improvement in OSA was associated with greater decreases in Aβ. We propose a model whereby OSA treatment may affect both Aβ release and clearance. Ann Neurol 2018 ANN NEUROL 2019;85:291–295.